Unicycive Therapeutics, Inc. (UNCY) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Unicycive Therapeutics, Inc. (UNCY) closed at USD 3.70 on 2026-10-14, a change of -21.6 % over the past year, with a market capitalization of USD 98.34M.

Unicycive Therapeutics, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Unicycive Therapeutics, Inc. key figures

Previous close

USD 3.70 (2026-10-14)

1-year change

-21.6 %

Market cap

USD 98.34M

Enterprise value

USD 39.25M

P/E ratio (trailing)

-2.09

P/E ratio (forward)

2.13

EPS (trailing)

-1.72

EPS (forward)

1.69

PEG ratio

n/a

Price to book

1.88

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

5.57

Employees

21

Analyst consensus (third-party)

none

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Unicycive Therapeutics, Inc.

Unicycive Therapeutics, Inc., a clinical-stage biotechnology company, identifies, develops, and commercializes therapies for the treatment of kidney diseases in the United States. It develops oxylanthanum carbonate, a lanthanum-based phosphate binding agent, which is for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI-494, a nicotinamide ester derivative and a selective ATP-sensitive mitochondrial potassium channel activator, which is in Phase I clinical trial for the treatment of acute kidney injury and pre-clinical stage for the treatment of chronic kidney disease. The company was incorporated in 2016 and is headquartered in Mountain View, California.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Unicycive Therapeutics, Inc. and compare it with other stocks.